Bluebird bio Inc (NASDAQ:BLUE) has a beta value of 0.77 and has seen 0.85 million shares traded in the recent trading session. The company, currently valued at $92.87M, closed the recent trade at $0.48 per share which meant it gained $0.01 on the day or 2.34% during that session. The BLUE stock price is -1052.08% off its 52-week high price of $5.53 and 6.25% above the 52-week low of $0.45. If we look at the company’s 10-day average daily trading volume, we find that it stood at 3.58 million shares traded. The 3-month trading volume is 7.32 million shares.
The consensus among analysts is that Bluebird bio Inc (BLUE) is Buy stock at the moment, with a recommendation rating of 2.80. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 4 have rated it as a Hold, with 2 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.36.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bluebird bio Inc (NASDAQ:BLUE) trade information
Sporting 2.34% in the green today, the stock has traded in the red over the last five days, with the highest price hit on recent trading when the BLUE stock price touched $0.48 or saw a rise of 5.88%. Year-to-date, Bluebird bio Inc shares have moved -65.44%, while the 5-day performance has seen it change -3.58%. Over the past 30 days, the shares of Bluebird bio Inc (NASDAQ:BLUE) have changed -16.33%. Short interest in the company has seen 49.42 million shares shorted with days to cover at 6.74.
Wall Street analysts have a consensus price target for the stock at $12.5, which means that the shares’ value could jump 96.16% from the levels at last check today. The projected low price target is $5.0 while the price target rests at a high of $25.0. In that case, then, we find that the latest price level in today’s session is -5108.33% off the targeted high while a plunge would see the stock gain -941.67% from the levels at last check today.
Bluebird bio Inc (BLUE) estimates and forecasts
Figures show that Bluebird bio Inc shares have outperformed across the wider relevant industry. The company’s shares have lost -52.31% over the past 6 months, with this year growth rate of 26.94%, compared to 17.50% for the industry. Revenue growth from the last financial year stood is estimated to be 193.30%.
9 analysts offering their estimates for the company have set an average revenue estimate of 18.05M for the current quarter. 8 have an estimated revenue figure of 27.85M for the next ending quarter.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 28.98% over the past 5 years. Earnings growth for 2024 is a modest 20.29% while over the next 5 years, the company’s earnings are expected to increase by 45.80%.
BLUE Dividends
Bluebird bio Inc is expected to release its next earnings report on 2024-Nov-05 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Bluebird bio Inc (NASDAQ:BLUE)’s Major holders
Insiders own 0.54% of the company shares, while shares held by institutions stand at 43.89% with a share float percentage of 44.13%. Investors are also buoyed by the number of investors in a company, with Bluebird bio Inc having a total of 203.0 institutions that hold shares in the company. The top two institutional holders are BLACKROCK INC. with over 15.44 million shares worth more than $15.2 million. As of 2024-06-30, BLACKROCK INC. held 14.1544% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 10.3 million shares as of 2024-06-30. The firm’s total holdings are worth over $10.14 million and represent 9.4422% of shares outstanding.
